Search Results - "LIENARD, Danielle"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Pattern and clinical significance of cancer‐testis gene expression in head and neck squamous cell carcinoma by Cuffel, Cyril, Rivals, Jean‐Paul, Zaugg, Yannick, Salvi, Suzanne, Seelentag, Walter, Speiser, Daniel E., Liénard, Danielle, Monnier, Philippe, Romero, Pedro, Bron, Luc, Rimoldi, Donata

    Published in International journal of cancer (01-06-2011)
    “…Cancer‐testis (CT) antigens comprise families of tumor‐associated antigens that are immunogenic in patients with various cancers. Their restricted expression…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma by Wilgenhof, Sofie, Du Four, Stephanie, Vandenbroucke, Frederik, Everaert, Hendrik, Salmon, Isabelle, Liénard, Danielle, Marmol, Véronique Del, Neyns, Bart

    Published in Journal of immunotherapy (1997) (01-04-2013)
    “…Ipilimumab, a CTLA-4-blocking monoclonal antibody, improved the overall survival (OS) of advanced melanoma patients treated in prospective clinical trials. We…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Enhanced Generation of Specific Tumor-Reactive CTL In Vitro by Selected Melan-A/MART-1 Immunodominant Peptide Analogues by Valmori, Danila, Fonteneau, Jean-Francois, Lizana, Concepcion Maranon, Gervois, Nadine, Lienard, Danielle, Rimoldi, Donata, Jongeneel, Victor, Jotereau, Francine, Cerottini, Jean-Charles, Romero, Pedro

    Published in The Journal of immunology (1950) (15-02-1998)
    “…The Melan-A/MART-1 gene, which is expressed by normal melanocytes as well as by most fresh melanoma samples and melanoma cell lines, codes for Ags recognized…”
    Get full text
    Journal Article
  15. 15

    Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure by Schreuer, Max S, Chevolet, Ines L, Jansen, Yanina J, Seremet, Teofila C, Wilgenhof, Sofie, Liénard, Danielle, Del Marmol, Veronique, Neyns, Bart

    Published in Melanoma research (01-02-2015)
    “…The aim of this study was to determine the activity of ipilimumab (ipi)-based therapy after treatment failure with a BRAF inhibitor (BRAFi). Sixty-four…”
    Get full text
    Journal Article
  16. 16

    Lack of BRAF mutations in uveal melanoma by RIMOLDI, Donata, SALVI, Suzanne, LIENARD, Danielle, LEJEUNE, Ferdy J, SPEISER, Daniel, ZOGRAFOS, Leonidas, CEROTTINI, Jean-Charles

    Published in Cancer research (Chicago, Ill.) (15-09-2003)
    “…RAF proteins are serine/threonine kinases that mediate cellular responses to growth signals by activating the mitogen-activated protein kinase pathway…”
    Get full text
    Journal Article
  17. 17
  18. 18
  19. 19

    Ex vivo detectable human CD8 T-Cell responses to cancer-testis antigens by BAUMGAERTNER, Petra, RUFER, Nathalie, DEVEVRE, Estelle, DERRE, Laurent, RIMOLDI, Donata, GELDHOF, C Hristine, VOELTER, Verena, LIENARD, Danielle, ROMERO, Pedro, SPEISER, Daniel E

    Published in Cancer research (Chicago, Ill.) (15-02-2006)
    “…Clinical trials have shown that strong tumor antigen-specific CD8 T-cell responses are difficult to induce but can be achieved for T-cells specific for…”
    Get full text
    Journal Article
  20. 20

    Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test by Seremet, Teofila, Haccuria, Amaryllis, Lienard, Danielle, Del Marmol, Véronique, Neyns, Bart

    Published in Melanoma research (01-02-2019)
    “…The combination of BRAF and MEK inhibitors is a standard therapeutic option for patients with metastatic melanoma with BRAF-mutated tumors. This type of…”
    Get full text
    Journal Article